Advertisement

Pharmaceutical Medicine

, Volume 29, Issue 3, pp 155–167 | Cite as

Nanoparticle-Mediated Delivery of Therapeutic Drugs

  • Nisha Ponnappan
  • Archana Chugh
Review Article

Abstract

Nanotechnology-based pharmaceutics is a fast emerging field in the diagnosis and therapy of a number of human diseases, including cancer. Nanoparticles offer a stable means to achieve targeted drug delivery to various cells and tissues. They have been investigated for drug delivery to different tumor tissues, to brain where the blood–brain barrier poses a significant problem in the delivery of effective therapeutic molecules, to ocular tissues and also for eliciting immune response via delivery of vaccines. Particularly, the small size of nanoparticles facilitates their easy access to a wide range of cells and tissues. Further, the size of nanoparticles can be controlled and their surface can be modified with desired ligands and receptors to specifically target cells of interest as well as achieve controlled drug release. Research is being carried out on numerous biological and synthetic nanoparticles. Diverse strategies are being developed to improve their stability, specificity and drug delivery efficiency. Nanoparticles have been also used in conjunction with cell-penetrating peptides for efficient drug delivery. Cell-penetrating peptides serve as efficient nanocarriers owing to their inherent ability to cross the plasma membrane barrier and deliver cargo to intracellular targets. Modification of nanoparticles with cell-penetrating peptides further increases their efficacy for increased permeation into varied cells and tissues. The current review focuses on different classes of nanoparticles and their application in the treatment of several types of diseases.

Keywords

Silver Nanoparticles Gold Nanoparticles Human Papilloma Virus Bacterial Vaginosis PLGA Nanoparticles 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

NP is thankful to the University Grants Commission, New Delhi, India, for the award of Junior and Senior Research Fellowship for pursuing doctoral research. NP and AC have no conflict of interests to declare. No funding was received for this article.

References

  1. 1.
    Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11:S81–91.PubMedGoogle Scholar
  2. 2.
    Chakraborty C, Pal S, Doss GPC, Wen Z-H, Lin C-S. Nanoparticles as “smart” pharmaceutical delivery. Front Biosci (Landmark Ed). 2013;18:1030–50.PubMedGoogle Scholar
  3. 3.
    De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3:133–49.Google Scholar
  4. 4.
    Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473–80.PubMedGoogle Scholar
  5. 5.
    Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. American Chemical Society; 2011;8:2101–41.Google Scholar
  6. 6.
    Stanley S. Biological nanoparticles and their influence on organisms. Curr Opin Biotechnol. 2014;28C:69–74.Google Scholar
  7. 7.
    Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O-E, Hernandez-Avila M, et al. Four year efficacy of prophylactic human papilloma virus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.PubMedGoogle Scholar
  8. 8.
    Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31:5745–53.PubMedGoogle Scholar
  9. 9.
    Wu W, Hsiao SC, Carrico ZM, Francis MB. Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem Int Ed Engl. 2009;48:9493–7.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Takamura S, Niikura M, Li T-C, Takeda N, Kusagawa S, Takebe Y, et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther. 2004;11:628–35.PubMedGoogle Scholar
  11. 11.
    Yoo J-W, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10:521–35.PubMedGoogle Scholar
  12. 12.
    Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, et al. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv. 2013;2013:905091.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Cormode DP, Jarzyna PA, Mulder WJM, Fayad ZA. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev. 2010;62:329–38.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126:16316–7.PubMedGoogle Scholar
  15. 15.
    Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008;8:3715–23.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Ding Y, Wang Y, Zhou J, Gu X, Wang W, Liu C, et al. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials. 2014;35:7214–27.PubMedGoogle Scholar
  17. 17.
    McMahon KM, Thaxton CS. High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin Drug Deliv. 2014;11:231–47.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Paul S, Chugh A. Assessing the role of ayurvedic “Bhasms” as ethno-nanomedicine in the metal based nanomedicine patent regime. J Intellect Prop Rights. 2011;16:509–15.Google Scholar
  19. 19.
    Thirumurugan G, Dhanaraju MD. Novel biogenic metal nanoparticles for pharmaceutical applications. Adv Sci Lett. American Scientific Publishers; 2011;4:339–48.Google Scholar
  20. 20.
    Thaxton CS, Rosi NL, Mirkin CA. Optically and chemically encoded nanoparticle materials for DNA and protein detection. MRS Bull. Cambridge University Press; 2011;30:376–80.Google Scholar
  21. 21.
    Sreeprasad TS, Pradeep T. Noble metal nanoparticles. In: Vajtai R, editor. Springer Handb. Nanomater. SE-9. Springer, Berlin; 2013. p. 303–88.Google Scholar
  22. 22.
    Conde J, Edelman ER, Artzi N. Target-responsive DNA / RNA nanomaterials for microRNA sensing and inhibition: the Jack-of-all-trades in cancer nanotheranostics? Adv Drug Deliv Rev. Elsevier B.V.; 2015;81:169–83.Google Scholar
  23. 23.
    Gurunathan S, Han JW, Kwon D-N, Kim J-H. Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. Nanoscale Res Lett. 2014;9:373.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Selvaraj M, Pandurangan P, Ramasami N, Rajendran SB, Sangilimuthu SN, Perumal P. Highly potential antifungal activity of quantum-sized silver nanoparticles against Candida albicans. Appl Biochem Biotechnol. 2014;173:55–66.PubMedGoogle Scholar
  25. 25.
    Rai M, Deshmukh SD, Ingle AP, Gupta IR, Galdiero M, Galdiero S. Metal nanoparticles: the protective nanoshield against virus infection. Crit Rev Microbiol. 2014;7828:1–11.Google Scholar
  26. 26.
    Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci. 2004;275:177–82.PubMedGoogle Scholar
  27. 27.
    Feng QL, Wu J, Chen GQ, Cui FZ, Kim TN, Kim JO. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res. 2000;52:662–8.PubMedGoogle Scholar
  28. 28.
    Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD. Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett Appl Microbiol. 1997;25:279–83.PubMedGoogle Scholar
  29. 29.
    Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnol. 2010;8:1.Google Scholar
  30. 30.
    Lu L, Sun RW-Y, Chen R, Hui C-K, Ho C-M, Luk JM, et al. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther. 2008;13:253–62.PubMedGoogle Scholar
  31. 31.
    Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006;128:2115–20.PubMedGoogle Scholar
  32. 32.
    Conde J, Bao C, Cui D, Baptista PV, Tian F. Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics. J Control Release. 2014;183:87–93.PubMedGoogle Scholar
  33. 33.
    Saha B, Bhattacharya J, Mukherjee A, Ghosh AK, Santra CR, Dasgupta AK, et al. In vitro structural and functional evaluation of gold nanoparticles conjugated antibiotics. Nanoscale Res Lett. Springer; 2007;2:614–22.Google Scholar
  34. 34.
    Craig GE, Brown SD, Lamprou DA, Graham D, Wheate NJ. Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval? Inorg Chem. 2012;51:3490–7.PubMedGoogle Scholar
  35. 35.
    Chen Y-H, Tsai C-Y, Huang P-Y, Chang M-Y, Cheng P-C, Chou C-H, et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm. 2007;4:713–22.PubMedGoogle Scholar
  36. 36.
    Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res. 2007;24:1415–26.PubMedGoogle Scholar
  37. 37.
    Conde J, Ambrosone A, Sanz V, Hernandez Y, Marchesano V, Tian F, et al. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano. American Chemical Society; 2012;6:8316–24.Google Scholar
  38. 38.
    Conde J, Tian F, Hernández Y, Bao C, Cui D, Janssen K-P, et al. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials. 2013;34:7744–53.PubMedGoogle Scholar
  39. 39.
    Conde J, Rosa J, de la Fuente JM, Baptista PV. Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. Biomaterials. 2013;34:2516–23.PubMedGoogle Scholar
  40. 40.
    Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, et al. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague–Dawley rats. Inhal Toxicol. 2008;20:575–83.PubMedGoogle Scholar
  41. 41.
    Asharani PV, Lian Wu Y, Gong Z, Valiyaveettil S. Toxicity of silver nanoparticles in zebrafish models. Nanotechnology. 2008;19:255102.PubMedGoogle Scholar
  42. 42.
    Chen Z, Meng H, Xing G, Chen C, Zhao Y, Jia G, et al. Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett. 2006;163:109–20.PubMedGoogle Scholar
  43. 43.
    Han N, Yang YY, Wang S, Zheng S, Fan W. Polymer-based cancer nanotheranostics: retrospectives of multi-functionalities and pharmacokinetics. Curr Drug Metab. 2013;14:661–74.PubMedGoogle Scholar
  44. 44.
    Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA–mPEG nanoparticles. Int J Pharm. 2001;221:143–52.PubMedGoogle Scholar
  45. 45.
    Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–34.PubMedGoogle Scholar
  46. 46.
    Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim S-B, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108:241–50.PubMedGoogle Scholar
  47. 47.
    Luk BT, Fang RH, Zhang L. Lipid- and polymer-based nanostructures for cancer theranostics. Theranostics. 2012;2:1117–26.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Hu L, Sun Y, Wu Y. Advances in chitosan-based drug delivery vehicles. Nanoscale. 2013;5:3103–11.PubMedGoogle Scholar
  49. 49.
    Du H, Cai X, Zhai G. Advances in the targeting molecules modified chitosan-based nanoformulations. Curr Drug Targets. 2013;14:1034–52.PubMedGoogle Scholar
  50. 50.
    De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159–68.PubMedGoogle Scholar
  51. 51.
    Jeong Y-I, Jin S-G, Kim I-Y, Pei J, Wen M, Jung T-Y, et al. Doxorubicin-incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro. Colloids Surf B Biointerfaces. 2010;79:149–55.PubMedGoogle Scholar
  52. 52.
    Ragelle H, Vandermeulen G, Préat V. Chitosan-based siRNA delivery systems. J Control Release. 2013;172:207–18.PubMedGoogle Scholar
  53. 53.
    Puri A, Loomis K, Smith B, Lee J-H, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26:523–80.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Mallick S, Choi JS. Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. J Nanosci Nanotechnol. 2014;14:755–65.PubMedGoogle Scholar
  55. 55.
    Rastogi V, Yadav P, Bhattacharya SS, Mishra AK, Verma N, Verma A, et al. Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J Drug Deliv. 2014;2014:670815.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Gomez-Gualdrón DA, Burgos JC, Yu J, Balbuena PB. Carbon nanotubes: engineering biomedical applications. Prog Mol Biol Transl Sci. 2011;104:175–245.PubMedGoogle Scholar
  57. 57.
    Hirsch A. Functionalization of single-walled carbon nanotubes. Angew Chem Int Ed Engl. 2002;41:1853–9.PubMedGoogle Scholar
  58. 58.
    Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012;33:3324–33.PubMedGoogle Scholar
  59. 59.
    Zhang W, Zhang D, Tan J, Cong H. Carbon nanotube exposure sensitize human ovarian cancer cells to paclitaxel. J Nanosci Nanotechnol. 2012;12:7211–4.PubMedGoogle Scholar
  60. 60.
    Ji Z, Lin G, Lu Q, Meng L, Shen X, Dong L, et al. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J Colloid Interface Sci. 2012;365:143–9.PubMedGoogle Scholar
  61. 61.
    Huang Y-P, Lin I-J, Chen C-C, Hsu Y-C, Chang C-C, Lee M-J. Delivery of small interfering RNAs in human cervical cancer cells by polyethylenimine-functionalized carbon nanotubes. Nanoscale Res Lett. 2013;8:267.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Pruthi J, Mehra NK, Jain NK. Macrophages targeting of amphotericin B through mannosylated multiwalled carbon nanotubes. J Drug Target. 2012;20:593–604.PubMedGoogle Scholar
  63. 63.
    Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. 2014;39:268–307.Google Scholar
  64. 64.
    Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7:295–304.PubMedGoogle Scholar
  65. 65.
    Kojima C, Suehiro T, Watanabe K, Ogawa M, Fukuhara A, Nishisaka E, et al. Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems. Acta Biomater. 2013;9:5673–80.PubMedGoogle Scholar
  66. 66.
    Gajbhiye V, Ganesh N, Barve J, Jain NK. Synthesis, characterization and targeting potential of zidovudine loaded sialic acid conjugated-mannosylated poly(propyleneimine) dendrimers. Eur J Pharm Sci. 2013;48:668–79.PubMedGoogle Scholar
  67. 67.
    Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res. 2001;7:3606–12.PubMedGoogle Scholar
  68. 68.
    Biswas S, Deshpande PP, Navarro G, Dodwadkar NS, Torchilin VP. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials. 2013;34:1289–301.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Xu R, Wang Y, Wang X, Jeong E-K, Parker DL, Lu Z-R. In vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent. Exp Biol Med (Maywood). 2007;232:1081–9.PubMedGoogle Scholar
  70. 70.
    Kannan RM, Nance E, Kannan S, Tomalia DA. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J Intern Med. 2014;276:579–617.PubMedGoogle Scholar
  71. 71.
    Jones CF, Campbell RA, Franks Z, Gibson CC, Thiagarajan G, Vieira-de-Abreu A, et al. Cationic PAMAM dendrimers disrupt key platelet functions. Mol Pharm. 2012;9:1599–611.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Dutta T, Garg M, Dubey V, Mishra D, Singh K, Pandita D, et al. Toxicological investigation of surface engineered fifth generation poly (propyleneimine) dendrimers in vivo. Nanotoxicology. Informa Healthcae; 2008;2:62–70.Google Scholar
  73. 73.
    Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55:1189–93.PubMedGoogle Scholar
  74. 74.
    Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA. 1991;88:1864–8.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Erazo-Oliveras A, Najjar K, Dayani L, Wang T-Y, Johnson GA, Pellois J-P. Protein delivery into live cells by incubation with an endosomolytic agent. Nat Methods. 2014;11:861–7.PubMedCentralPubMedGoogle Scholar
  76. 76.
    Arribat Y, Talmat-Amar Y, Paucard A, Lesport P, Bonneaud N, Bauer C, et al. Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease. Acta Neuropathol Commun. 2014;2:86.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Lindberg S, Muñoz-Alarcón A, Helmfors H, Mosqueira D, Gyllborg D, Tudoran O, et al. PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors. Int J Pharm. 2013;441:242–7.PubMedGoogle Scholar
  78. 78.
    Sayers EJ, Cleal K, Eissa NG, Watson P, Jones AT. Distal phenylalanine modification for enhancing cellular delivery of fluorophores, proteins and quantum dots by cell penetrating peptides. J Control Release. 2014;195:55–62.PubMedGoogle Scholar
  79. 79.
    Chen Z, Zhang P, Cheetham AG, Moon JH, Moxley JW, Lin Y-A, et al. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. J Control Release. 2014;191:123–30.PubMedGoogle Scholar
  80. 80.
    Chugh A, Eudes F, Shim Y-S. Cell-penetrating peptides: nanocarrier for macromolecule delivery in living cells. IUBMB Life. 2010;62:183–93.PubMedGoogle Scholar
  81. 81.
    Madani F, Lindberg S, Langel U, Futaki S, Gräslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011;2011:414729.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Regberg J, Eriksson JNK, Langel U. Cell-penetrating peptides: from cell cultures to in vivo applications. Front Biosci (Elite Ed). 2013;5:509–16.PubMedGoogle Scholar
  83. 83.
    Liu J, Zhang B, Luo Z, Ding X, Li J, Dai L, et al. Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale. 2015;7:3614–26.PubMedGoogle Scholar
  84. 84.
    Vasconcelos A, Vega E, Pérez Y, Gómara MJ, García ML, Haro I. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery. Int J Nanomed. 2015;10:609–31.Google Scholar
  85. 85.
    Padari K, Koppel K, Lorents A, Hällbrink M, Mano M, Pedroso de Lima MC, et al. S4(13)-PV cell-penetrating peptide forms nanoparticle-like structures to gain entry into cells. Bioconjug Chem. 2010;21:774–83.PubMedGoogle Scholar
  86. 86.
    Liu L, Xu K, Wang H, Tan PKJ, Fan W, Venkatraman SS, et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol. 2009;4:457–63.PubMedGoogle Scholar
  87. 87.
    Zhang Z-H, Zhang Y-L, Zhou J-P, Lv H-X. Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. Int J Nanomed. 2012;7:3333–9.Google Scholar
  88. 88.
    Fan T, Chen C, Guo H, Xu J, Zhang J, Zhu X, et al. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur J Pharm Biopharm. 2014;88:518–28.PubMedGoogle Scholar
  89. 89.
    Liu BR, Winiarz JG, Moon J-S, Lo S-Y, Huang Y-W, Aronstam RS, et al. Synthesis, characterization and applications of carboxylated and polyethylene-glycolated bifunctionalized InP/ZnS quantum dots in cellular internalization mediated by cell-penetrating peptides. Colloids Surf B Biointerfaces. Elsevier B.V.; 2013;111:162–70.Google Scholar
  90. 90.
    Santra S, Yang H, Stanley JT, Holloway PH, Moudgil BM, Walter G, et al. Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem Commun (Camb). 2005:3144–6.Google Scholar
  91. 91.
    Hu Y, Xu B, Ji Q, Shou D, Sun X, Xu J, et al. A mannosylated cell-penetrating peptide-graft-polyethylenimine as a gene delivery vector. Biomaterials. 2014;35:4236–46.PubMedGoogle Scholar
  92. 92.
    Zhao D, Zhuo R-X, Cheng S-X. Modification of calcium carbonate based gene and drug delivery systems by a cell-penetrating peptide. Mol Biosyst. 2012;8:3288–94.PubMedGoogle Scholar
  93. 93.
    Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release. 2004;98:317–23.PubMedGoogle Scholar
  94. 94.
    Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev. 2011;63:152–60.PubMedGoogle Scholar
  95. 95.
    Ishitsuka T, Akita H, Harashima H. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung. J. Control. Release. 2011;154:77–83.PubMedGoogle Scholar
  96. 96.
    Kusumoto K, Akita H, Ishitsuka T, Matsumoto Y, Nomoto T, Furukawa R, et al. Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. ACS Nano. 2013;7:7534–41.PubMedGoogle Scholar
  97. 97.
    Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, et al. MITO-Porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta. 2008;1778:423–32.PubMedGoogle Scholar
  98. 98.
    Suzuki R, Yamada Y, Harashima H. Efficient cytoplasmic protein delivery by means of a multifunctional envelope-type nano device. Biol Pharm Bull. 2007;30:758–62.PubMedGoogle Scholar
  99. 99.
    Sakurai Y, Hatakeyama H, Akita H, Harashima H. Improvement of doxorubicin efficacy using liposomal anti-Polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm. 2014;11:2713–9.PubMedGoogle Scholar
  100. 100.
    Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz YC, et al. Nanomedicines: addressing the scientific and regulatory gap. Ann NY Acad Sci. 2014;1313:35–56.PubMedGoogle Scholar
  101. 101.
    Bawa R. Nanoparticle-based therapeutics in humans: a survey. Nanotechnol Law Bus. 2008;5:135–55.Google Scholar
  102. 102.
    Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761–9.PubMedGoogle Scholar
  103. 103.
    Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 2013;21:1096–103.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Xu L, Huang C-C, Huang W, Tang W-H, Rait A, Yin YZ, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1:337–46.PubMedGoogle Scholar
  105. 105.
    Xu L, Frederik P, Pirollo KF, Tang W-H, Rait A, Xiang L-M, et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther. 2002;13:469–81.PubMedGoogle Scholar
  106. 106.
    Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611–9.PubMedGoogle Scholar
  107. 107.
    Al-Batran S-E, Geissler M, Seufferlein T, Oettle H. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. Oncol Res Treat. 2014;37:128–34.PubMedGoogle Scholar
  108. 108.
    Ko Y-J, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013;14:769–76.PubMedGoogle Scholar
  109. 109.
    Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041–53.PubMedGoogle Scholar
  110. 110.
    Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72:191–202.PubMedGoogle Scholar
  111. 111.
    Ranade AA, Bapsy PP, Nag S, Raghunadharao D, Raina V, Advani SH, et al. A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline. Asia Pac J Clin Oncol. 2013;9:176–81.PubMedGoogle Scholar
  112. 112.
    Cheng Y, Dai Q, Morshed RA, Fan X, Wegscheid ML, Wainwright DA, et al. Blood–brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small. 2014;10:5137–50.PubMedGoogle Scholar
  113. 113.
    Zhang C, Zheng X, Wan X, Shao X, Liu Q, Zhang Z, et al. The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer’s disease. J Control Release. 2014;192:317–24.PubMedGoogle Scholar
  114. 114.
    Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems—recent advances. Prog Retin Eye Res. 1998;17:33–58.PubMedGoogle Scholar
  115. 115.
    Kalita D, Shome D, Jain VG, Chadha K, Bellare JR. In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. Am J Ophthalmol. 2014;157:1109–15.PubMedGoogle Scholar
  116. 116.
    Rajala A, Wang Y, Zhu Y, Ranjo-Bishop M, Ma J-X, Mao C, et al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 2014;14:5257–63.PubMedGoogle Scholar
  117. 117.
    Read SP, Cashman SM, Kumar-Singh R. POD nanoparticles expressing GDNF provide structural and functional rescue of light-induced retinal degeneration in an adult mouse. Mol Ther. 2010;18:1917–26.PubMedCentralPubMedGoogle Scholar
  118. 118.
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.PubMedGoogle Scholar
  119. 119.
    Sehgal K, Dhodapkar KM, Dhodapkar MV. Targeting human dendritic cells in situ to improve vaccines. Immunol Lett. 2014;162:59–67.PubMedGoogle Scholar
  120. 120.
    Mishra N, Tiwari S, Vaidya B, Agrawal GP, Vyas SP. Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J Drug Target. 2011;19:67–78.PubMedGoogle Scholar
  121. 121.
    Thomann J-S, Heurtault B, Weidner S, Brayé M, Beyrath J, Fournel S, et al. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials. 2011;32:4574–83.PubMedGoogle Scholar
  122. 122.
    Aditya NP, Vathsala PG, Vieira V, Murthy RSR, Souto EB. Advances in nanomedicines for malaria treatment. Adv Colloid Interface Sci. 2013;201–202:1–17.PubMedGoogle Scholar
  123. 123.
    Tahamtan A, Ghaemi A, Gorji A, Kalhor H, Sajadian A, Tabarraei A, et al. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. J Biomed Sci. 2014;21:69.PubMedCentralPubMedGoogle Scholar
  124. 124.
    Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012;33:4957–64.PubMedGoogle Scholar
  125. 125.
    Moni SS, Safhi MM, Barik BB. Nanoparticles for triggering and regulation of immune response of vaccines: perspective and prospective. Curr Pharm Biotechnol. 2014;14:1242–9.Google Scholar
  126. 126.
    Fukasawa M, Shimizu Y, Shikata K, Nakata M, Sakakibara R, Yamamoto N, et al. Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett. 1998;441:353–6.PubMedGoogle Scholar
  127. 127.
    Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF. Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2:544–68.PubMedGoogle Scholar
  128. 128.
    Stone V, Johnston H, Clift MJD. Air pollution, ultrafine and nanoparticle toxicology: cellular and molecular interactions. IEEE Trans Nanobiosci. 2007;6:331–40.Google Scholar
  129. 129.
    Bhabra G, Sood A, Fisher B, Cartwright L, Saunders M, Evans WH, et al. Nanoparticles can cause DNA damage across a cellular barrier. Nat Nanotechnol. 2009;4:876–83.PubMedGoogle Scholar
  130. 130.
    Sharma HS, Sharma A. Nanoparticles aggravate heat stress induced cognitive deficits, blood–brain barrier disruption, edema formation and brain pathology. Prog Brain Res. 2007;162:245–73.PubMedGoogle Scholar
  131. 131.
    Oberdörster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect. 2004;112:1058–62.PubMedCentralPubMedGoogle Scholar
  132. 132.
    Paliwal R, Babu RJ, Palakurthi S. Nanomedicine scale-up technologies: feasibilities and challenges. AAPS PharmSciTech. 2014;15:1527–34.PubMedGoogle Scholar
  133. 133.
    Kanazawa T, Sugawara K, Tanaka K, Horiuchi S, Takashima Y, Okada H. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles. Eur J Pharm Biopharm. 2012;81:470–7.PubMedGoogle Scholar
  134. 134.
    Shah PP, Desai PR, Channer D, Singh M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release. 2012;161:735–45.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Shan W, Zhu X, Liu M, Li L, Zhong J, Sun W, et al. Overcoming the Diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano. 2015;9:2345–56.PubMedGoogle Scholar
  136. 136.
    Yao H, Wang K, Wang Y, Wang S, Li J, Lou J, et al. Enhanced blood–brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system. Biomaterials. 2015;37:345–52.PubMedGoogle Scholar
  137. 137.
    Wang H, Zhao Y, Wang H, Gong J, He H, Shin MC, et al. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. J Control Release. 2014;192:47–56.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Kusuma School of Biological SciencesIndian Institute of Technology DelhiNew DelhiIndia

Personalised recommendations